Ennature Biopharma: FY26 Financials, Segment Mix, and Strategic Nutraceutical Expansion
India Glycols Ltd 路 Investor Presentation 路 02 Sept 2026, 10:15 pm
Ennature Biopharma: FY26 Financials, Segment Mix, and Strategic Nutraceutical Expansion As of Sep'26, Ennature Biopharma (demerged from India Glycols) reported FY26 revenue of INR 246 Cr, a 40.1% gross margin, and an 11.9% EBITDA margin. The firm utilizes robust cash flows from its mature Plant-based APIs (67% of sales) to fund its high-growth, high-margin Nutraceuticals segment (17% of sales). Driven by 83% export penetration in nutraceuticals and global USFDA/EU-GMP certifications, Ennature鈥檚 strategic roadmap targets scaling to 6-8 clinically validated branded ingredients, launching one new API annually, and aggressively expanding higher-value market share across US and European health platforms.
Original exchange filing (PDF)
More announcements from India Glycols Ltd
- Please find attached. 路 17 Nov 2026
- Please find atached. 路 13 Nov 2026
- India Glycols Limited has informed the Exchange about General Updates 路 13 Nov 2026
- Please find attached. 路 13 Nov 2026
- India Glycols Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 13 Nov 2026
- Please refer to attachment. 路 13 Nov 2026
- Please find attached 路 18 Nov 2026
- Please find attached 路 18 Nov 2026
